NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression newsBy Elizabeth AspinallApril 15, 2024See the press release on Business Wire
